SF3B1 and breast carcinoma: Based on its ability to target both tRNA metabolism and splicing, we propose a new therapeutic application for the riboside analogue 8-azaguanine in treating patients harbouring SF3B1 mutations, such as breast cancer, uveal melanoma, myelodysplastic syndromes, acute myeloid leukaemia and beyond.